Gene Therapy in Oncology: Innovation to Commercialization, Competitive Landscape, Technological Advancements, Market Opportunities & Future Directions

DelveInsight report Gene Therapies in Oncology - Innovation to Commercialization: Competitive Landscape, Technological Advancements, Market Opportunities & Future Directions, 2018 includes Comprehensive Insights on Cancer Gene Therapy by Market Trends, Competitive Landscape, Clinical Trials, Regulatory Considerations, Potential Geographies Licensing Opportunities, Top Cancer Indications, Vectors (Viral, Non-Viral, Engineered nucleases) and Advancements in Technology. It provides information across the entire gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, and funding and licensing opportunities. Using the propriety DelveInsight Competitive Matrix models, the report also provides the first in class market analytics providing predictive analysis of early market winners of the clinical therapies in a demographic presentation view.

It has covered ~50 gene therapies covering 34 Pharmaceutical companies. Studies have been performed for approximately 60+ specific indications under Oncology. The companies are utilizing 26 different technology platforms which have inherent uniqueness and robustness. The Report also gives insights about the vectors usage in Gene therapy which are approximately 82% for viral vectors, 11% for the Non-Viral vectors and 7% for the Bacterial vectors.

The power of cell and gene therapies targeted for the life-threatening and high unmet need diseases have been the driving force behind academics, small biotech firms; and now large pharmaceutical companies which are also actively investing time and resources in this rapidly evolving area. The concept of human gene therapies had emerged in 1989, with the first approved human gene therapy trial of Rosenberg et al., which investigated the use of human tumor-infiltrating lymphocytes (TIL) modified genetically by introducing the gene coding for resistance to neomycin into TIL for patients with advanced melanoma. The discipline as a whole received a moderate push during the 1990s until the elucidation of the human genome in 2003.There has been no looking back since then, and thereafter leading up to a stage where gene therapy is touted as the next big thing in the healthcare space; and is set to break the existing barriers and create new horizons.

Report Scope:

The report covers a descriptive account of Gene Therapy in oncology, inclusive of its historical timeline & its evolution over the years, types, and vectors along with the corresponding gene-transfer methods as well as delivery techniques, apart from advancements in technologies
Coverage of cancer gene therapy candidates under development worldwide, showcasing their relative positioning in global Oncology therapeutic space
Breakdown of Pipeline candidates across different phases, emerging trends and comparative analysis of the products with detailed clinical profiles, Targets, Designations, Technologies, Combination drugs along with product development activities
In-depth analysis of developmental gene therapy molecules based on cancer indication, types of vector, clinical staging and by geography
Comprehensive insight is provided into licensing & collaboration opportunities and funding details for emerging gene therapies
Matrix analysis, based on clinical and commercial scoring of promising therapies under late-stage development, to predict their regulatory success and subsequent market penetration
Mapping of Clinical trials based upon the trial design, targeted cancer indications and geography
A detailed review of the regulatory guidelines/framework for the approval of gene therapy across the 7MM [US, EU5 countries and Japan]
Additionally, an all-inclusive account of the currently marketed gene therapies in Oncology and their commercial impact in the market covered
The report provides an edge while formulating business strategies by enabling comprehensive understanding of the historical trends, present challenges and future developmental opportunities for Cancer Gene Therapy; which will help in prudently positioning in the market against competitors

List Of Tables

Table 1: Gene Therapy in Oncology Analysis by Total Products, 2018.

Table 2: Gene Therapy in Oncology Clinical Pipeline Analysis by Region (N), 2018.

Table 3: Gene Therapy in Oncology Analysis by Regulatory Designations, 2018.

Table 4: Gene Therapy in Oncology Analysis by Company Collaborations, 2018.

Table 5: Gene Therapy in Oncology Analysis by Product Type, 2018.

Table 6: Gene Therapy in Oncology Analysis by Product Type - Combination Therapy , 2018.

Table 7: Gene Therapy in Oncology Analysis by Originator, 2018.

Table 8: Gene Therapy in Oncology Analysis by Pharmaceutical Companies, 2018.

Table 9: Gene Therapy in Oncology Analysis by Technology, 2018.

Table 10: Gene Therapy in Oncology Analysis by Targets, 2018.

Table 11: Gene Therapy in Oncology Analysis by Vectors, 2018.

Table 12: Gene Therapy in Oncology Analysis by Vectors, Products & Companies, 2018.

Table 13: Gene Therapy in Oncology Analysis by Viral Vectors (Phases), 2018.

Table 14: Gene Therapy in Oncology Analysis by Viral Vectors (Type), 2018.

Table 15: Gene Therapy in Oncology Analysis by Non-Viral Vectors (Phases), 2018.

Table 16: Marketed Gene Therapies in Oncology, 2018.

Table 17: Gene Therapy in Oncology Marketed Products Sales Analysis (Million), 2018.

Table 18: Market access status of EC-approved Cellular & Gene Therapies as of March 31, 2017.

Table 19: Descriptions of payment models for gene therapies.

Table 20:Top 10 Early Market Winners in Gene Therapies Oncology by Rank

List Of Figures

Figure 1: Gene Therapy in Oncology Analysis by Total Products (N), 2018.

Figure 2: Gene Therapy in Oncology Clinical Pipeline Analysis by Region (N), 2018.

Figure 3: Gene Therapy in Oncology Analysis by Regulatory Designations, 2018.

Figure 4: Gene Therapy in Oncology Analysis by Company Collaborations (%), 2018.

Figure 5: Gene Therapy in Oncology Analysis by Product Type (%), 2018.

Figure 6: Gene Therapy in Oncology Analysis by Product Type-Combination Therapy (N), 2018.

Figure 7: Gene Therapy in Oncology Analysis by Originator (%), 2018.

Figure 8: Gene Therapy in Oncology Analysis by Pharmaceutical Companies (Clinical vs Non-Clinical), 2018.

Figure 9: Gene Therapy in Oncology Analysis by Technology, 2018.

Figure 10: Gene Therapy in Oncology Analysis by Targets, 2018.

Figure 11: Gene Therapy in Oncology Analysis by Vectors, 2018.

Figure 12: Gene Therapy in Oncology Analysis by Viral Vectors (Phases), 2018.

Figure 13: Gene Therapy in Oncology Analysis by Viral Vectors (Type), 2018.

Figure 14: Gene Therapy in Oncology Analysis by Non-Viral Vectors (Phases), 2018.

Figure 15: Marketed Gene Therapies in Oncology, 2018.

Figure 16: Gene Therapy in Oncology Marketed Products Sales Analysis, 2018.

Figure 17: Competitive Matrix for Gene Therapy in Oncology Disease.

Figure 18: Market Drivers.

Figure 19: Market Barriers

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available